Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 1Colorectal Neoplasms 1CRC 1

Interventions

Paclitaxel 10trametinib 9dabrafenib 9pembrolizumab 5lenvatinib 5fosbretabulin 4Sorafenib 4Radiotherapy, Intensity-Modulated 4Doxorubicin 4Radiotherapy 3Cisplatin 3pazopanib 2efatutazone 2combretastatin 2cobimetinib 2cemiplimab 2atezolizumab 2aldesleukin 2Vemurafenib 2Trastuzumab 2Taxes 2Nivolumab 2Gefitinib 2Filgrastim 2Everolimus 2Docetaxel 2Carboplatin 2Bevacizumab 2zimberelimab 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Thyroid Carcinoma, Anaplastic × CCT239065 × Clear all
NCT05102292 2023-08-21

The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation

Shanghai Henlius Biotech

Phase 1/2 Unknown
25 enrolled
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡